<img height="1" width="1" style="display:none" src="https://www.facebook.com/tr?id=780280282443813&amp;ev=PageView&amp;noscript=1">
search

    Leap Therapeutics, Inc.

    verified_userVerify Profile
    Companies » Health Care » Pharmaceuticals & Biotechnology » Pharmaceuticals

    About Leap Therapeutics, Inc.

    Leap Therapeutics (NASDAQ: LPTX) is focused on developing targeted and immuno-oncology therapeutics. Leap's most advanced clinical candidate, DKN-01, is a humanized monoclonal antibody targeting the Dickkopf-1 (DKK1) protein, a Wnt pathway modulator. DKN-01 is in clinical trials in patients with esophagogastric, hepatobiliary, gynecologic, and prostate cancers. Leap's second clinical candidate, TRX518, is a humanized GITR agonist monoclonal antibody designed to enhance the immune system's anti-tumor response that is in advanced solid tumor studies. Source

    At A Glance

    • CAPITAL RAISE STATUS
      Not Currently Raising
    • FILING TYPE
      Public
    • PLATFORM TYPE
      NASDAQ
    • RAISED AMOUNT
      $X,XXX,XXX
    • PRE-MONEY EVAULATION
      $X,XXX,XXX
    • SIC CODE
      2834
    • NIN CODE
      ####
    • LEADERSHIP
      Chris Mirabelli, Ph.D.
    • FOUNDED
      2011
    • EMPLOYEES
      20
    • SECTOR
      Pharmaceuticals & Biotechnology
    • SUBSECTOR
      Pharmaceuticals

    Company Tags

    No articles found.

    China Biologic Products Holdings, Inc.

    China Biologic Products Holdings, Inc.

    China Biologic Products Holdings, Inc. (NASDAQ: CBPO), is a leading fully integrat...

    China Biologic Products Holdings, Inc. (NASDAQ:...

    Filing Type:    PU
    AtriCure, Inc.

    AtriCure, Inc.

    As a leading provider of innovative technologies for the treatment of Atrial Fibri...

    As a leading provider of innovative technologie...

    Filing Type:    PU
    WinSanTor, Inc.

    WinSanTor, Inc.

    WinSanTor’s mission is simple-develop a drug that works. We recognize that there...

    WinSanTor’s mission is simple-develop a drug ...

    Amount Raised:    $572,649.00
    Fundraising Status:    EC
    Filing Type:    CF
    ContraFect Corporation

    ContraFect Corporation

    ContraFect is a clinical-stage biotechnology company focused on discovering and de...

    ContraFect is a clinical-stage biotechnology co...

    Filing Type:    PU
    Applied Therapeutics, Inc.

    Applied Therapeutics, Inc.

    Applied Therapeutics is a clinical-stage biopharmaceutical company developing a pi...

    Applied Therapeutics is a clinical-stage biopha...

    Filing Type:    PU
    Moderna, Inc.

    Moderna, Inc.

    Moderna is advancing messenger RNA (mRNA) science to create a new class of transfo...

    Moderna is advancing messenger RNA (mRNA) scien...

    Filing Type:    PU
    Delee Corp

    Delee Corp

    At Delee we’re fundamentally changing not only the way cancer is detected but also...

    At Delee we’re fundamentally changing not only ...

    Amount Raised:    $492,503.00
    Fundraising Status:    EC
    Filing Type:    CF
    Idera Pharmaceuticals, Inc.

    Idera Pharmaceuticals, Inc.

    Idera Pharmaceuticals is a clinical-stage biopharmaceutical company developing nov...

    Idera Pharmaceuticals is a clinical-stage bioph...

    Filing Type:    PU
    ADiTx Therapeutics, Inc

    ADiTx Therapeutics, Inc

    The discovery of immunosuppressive (anti-rejection) drugs has made possible life-s...

    The discovery of immunosuppressive (anti-reject...

    Filing Type:    RA
    ©2025 National Investor Network. All Rights Reserved.